Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jul;124(1):87-92.
doi: 10.1111/bju.14666. Epub 2019 Feb 6.

Androgen deprivation therapy for prostate cancer and risk of dementia

David Robinson  1 , Hans Garmo  2   3 , Mieke Van Hemelrijck  3 , Jan-Erik Damber  4 , Ola Bratt  4 , Lars Holmberg  3 , Lars-Olof Wahlund  5 , Pär Stattin  6 , Jan Adolfsson  7
Affiliations
Observational Study

Androgen deprivation therapy for prostate cancer and risk of dementia

David Robinson et al. BJU Int. 2019 Jul.

Abstract

Objectives: To study whether androgen deprivation therapy (ADT), the mainstay treatment for advanced and disseminated prostate cancer, is associated with risk of dementia.

Methods: Risk of dementia in men with prostate cancer primarily managed with ADT or watchful waiting (WW) in the Prostate Cancer Database Sweden, PCBaSe, was compared with that in prostate cancer-free men, matched on birth year and county of residency. We used Cox regression to calculate the hazard ratios (HRs) for Alzheimer's and non-Alzheimer's dementia (vascular dementia, dementia secondary to other diseases or unspecified dementias) for different types and duration of ADT and oral antiandrogens (AAs) as well as for men managed with WW.

Results: A total of 25 967 men with prostate cancer and 121 018 prostate cancer-free men were followed for a median of 4 years. In both groups 6% of the men were diagnosed with dementia. In men with prostate cancer, gonadotropin-releasing hormone agonist treatment ( HR 1.15, 95% confidence interval [CI] 1.07-1.23) and orchiectomy (HR 1.60, 95% CI 1.32-1.93) were associated with an increased risk of dementia, as compared to no treatment in prostate cancer-free men; however, this increase in risk was only observed for non-Alzheimer's dementia and occurred from year 1-4 after start of ADT. No increase in risk for any type of dementia was observed for men treated with AAs or for men on WW.

Conclusion: This population-based cohort study does not support previous observations of an increased risk of Alzheimer's dementia for men on ADT; however, there was a small increase in risk of non-Alzheimer's dementia.

Keywords: #ADT; #Dementia; #PCSM; #ProstateCancer; androgen deprivation therapy; dementia.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Risk of dementia related to the duration of exposure by use of hazard ratios with 95% CIs, calculated in Cox proportional hazard regression models with age as a timescale. Men without prostate cancer were the reference group. AA, antiandrogen; Orch, orchiectomy;WW, watchful waiting.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of A . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–31 - PubMed
    1. Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016; 374: 523–32 - PMC - PubMed
    1. Moffat SD, Zonderman AB, Metter EJ et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004; 62: 188–93 - PubMed
    1. Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 2004; 39: 1633–9 - PubMed
    1. Butchart J, Birch B, Bassily R, Wolfe L, Holmes C. Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord 2013; 27: 153–6 - PubMed

Publication types

Substances